ABSTRACT
Sibutramine was approved by the U.S. FDA for use in
obesity treatment in 1997. It is one of only two medica-
tions (along with orlistat, approved in 1999) approved for
long-term use in the United States. The 2007 review of
rimonabant by the FDA called for additional neuropsychi-
atric safety data, and thus sibutramine remains the only
centrally acting agent approved for long-term use. This
review focuses on the use of sibutramine in medical
practices to help obese patients achieve and sustain health
benefits through weight loss.
